Radiation enhancement using focussed ultrasound-stimulated microbubbles for breast cancer: A Phase 1 clinical trial

• Published in: PLoS medicine Vol. 21; no. 5; p. e1004408
• Main Authors: Moore-Palhares, Daniel, Dasgupta, Archya, Saifuddin, Murtuza, Anzola Pena, Maria Lourdes, Prasla, Shopnil, Ho, Ling, Lu, Lin, Kung, Joseph, McNabb, Evan, Sannachi, Lakshmanan, Vesprini, Danny, Chen, Hanbo, Karam, Irene, Soliman, Hany, Szumacher, Ewa, Chow, Edward, Gandhi, Sonal, Trudeau, Maureen, Curpen, Belinda, Stanisz, Greg J., Kolios, Michael, Czarnota, Gregory J.
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 17.05.2024; Public Library of Science (PLoS)
• Subjects: Acute toxicity; Adult; Aged; Aged, 80 and over; Allergies; Apoptosis; Biology and Life Sciences; Breast cancer; Breast Neoplasms - diagnostic imaging; Breast Neoplasms - pathology; Breast Neoplasms - radiotherapy; Cancer therapies; Care and treatment; Cavitation; Cell death; Clinical trials; Contraindications; Dermatitis; Endothelial cells; Endothelium; Female; Fractionation; Health aspects; Health sciences; Humans; Magnetic Resonance Imaging; Medical imaging; Medical imaging equipment; Medical research; Medicine and Health Sciences; Medicine, Experimental; Metastases; Microbubbles; Microbubbles - therapeutic use; Microspheres; Middle Aged; Patients; Permeability; Product development; Prospective Studies; Quality management; Radiation; Radiation therapy; Radiotherapy; Research and analysis methods; Skin cancer; Terminology; Tomography; Treatment Outcome; Tumors; Ultrasonic imaging; Ultrasonic transducers; Ultrasound; Women; Canada; United States > US; Netherlands; Germany
• DOI: 10.1371/journal.pmed.1004408
• ISSN: 1549-1676; 1549-1277

Preclinical studies have demonstrated that tumour cell death can be enhanced 10- to 40-fold when radiotherapy is combined with focussed ultrasound-stimulated microbubble (FUS-MB) treatment. The acoustic exposure of microbubbles (intravascular gas microspheres) within the target volume causes bubble cavitation, which induces perturbation of tumour vasculature and activates endothelial cell apoptotic pathways responsible for the ablative effect of stereotactic body radiotherapy. Subsequent irradiation of a microbubble-sensitised tumour causes rapid increased tumour death. The study here presents the mature safety and efficacy outcomes of magnetic resonance (MR)-guided FUS-MB (MRgFUS-MB) treatment, a radioenhancement therapy for breast cancer. This prospective, single-center, single-arm Phase 1 clinical trial included patients with stages I-IV breast cancer with in situ tumours for whom breast or chest wall radiotherapy was deemed adequate by a multidisciplinary team (clinicaltrials.gov identifier: NCT04431674). Patients were excluded if they had contraindications for contrast-enhanced MR or microbubble administration. Patients underwent 2 to 3 MRgFUS-MB treatments throughout radiotherapy. An MR-coupled focussed ultrasound device operating at 800 kHz and 570 kPa peak negative pressure was used to sonicate intravenously administrated microbubbles within the MR-guided target volume. The primary outcome was acute toxicity per Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Secondary outcomes were tumour response at 3 months and local control (LC). A total of 21 female patients presenting with 23 primary breast tumours were enrolled and allocated to intervention between August/2020 and November/2022. Three patients subsequently withdrew consent and, therefore, 18 patients with 20 tumours were included in the safety and LC analyses. Two patients died due to progressive metastatic disease before 3 months following treatment completion and were excluded from the tumour response analysis. The prescribed radiation doses were 20 Gy/5 fractions (40%, n = 8/20), 30 to 35 Gy/5 fractions (35%, n = 7/20), 30 to 40 Gy/10 fractions (15%, n = 3/20), and 66 Gy/33 fractions (10%, n = 2/20). The median follow-up was 9 months (range, 0.3 to 29). Radiation dermatitis was the most common acute toxicity (Grade 1 in 16/20, Grade 2 in 1/20, and Grade 3 in 2/20). One patient developed grade 1 allergic reaction possibly related to microbubbles administration. At 3 months, 18 tumours were evaluated for response: 9 exhibited complete response (50%, n = 9/18), 6 partial response (33%, n = 6/18), 2 stable disease (11%, n = 2/18), and 1 progressive disease (6%, n = 1/18). Further follow-up of responses indicated that the 6-, 12-, and 24-month LC rates were 94% (95% confidence interval [CI] [84%, 100%]), 88% (95% CI [75%, 100%]), and 76% (95% CI [54%, 100%]), respectively. The study's limitations include variable tumour sizes and dose fractionation regimens and the anticipated small sample size typical for a Phase 1 clinical trial. MRgFUS-MB is an innovative radioenhancement therapy associated with a safe profile, potentially promising responses, and durable LC. These results warrant validation in Phase 2 clinical trials. clinicaltrials.gov, identifier NCT04431674.